In today’s briefing:
- Gracell Biotechnologies Inc (GRCL.US) – May Fail to Solve the Real Pain Points in CAR-T Field
- General Mills: A Disappointing Quarter For Short-Term Investors And Speculators
Gracell Biotechnologies Inc (GRCL.US) – May Fail to Solve the Real Pain Points in CAR-T Field
- The latest data of GC012F/GC007g at ASCO/EHA drove up share price, but the current clinical data do not necessarily guarantee the final druggability. So, we advise investors to be rational.
- Gracell’s pipeline may not solve the real pain points of CAR-T therapy. Until the global momentum of cell therapy is reversed, there’s no need to expect too much from Gracell.
- Gracell’s stock price would continue to fluctuate with positive clinical data or progress. However, the liquidity of this stock isn’t good. In this situation, both ups and downs are meaningless.
General Mills: A Disappointing Quarter For Short-Term Investors And Speculators
- General Mills has just reported its full fiscal year results and investors are not impressed.
- Expectations of lower organic revenue growth and uncertainties around profitability would likely continue to weigh on the share price.
- Long-term investors, however, could take advantage of this near-term dynamic while enjoying the higher dividend.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
